Paradigm collaborates with TESARO on molecular profiling

Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO’s TSR-011.

This may lead to more successful clinical trial outcomes as well as enable Paradigm to develop and commercialize potential diagnostic products.

Paradigm CEO Robert Penny noted: "Paradigm is utilizing decades of know how in successfully working with the pharmaceutical and diagnostic industry and merging those with our unique academic research abilities to craft personalized interrogations for clinical trial selection and provide accelerated translational treatment decisions in patient care."